Please enable JavaScript to continue using this application.

Compare $LYEL vs $TRDA | Chartloom

Compare

$LYEL vs $TRDA

Lyell Immunopharma Inc · Entrada Therapeutics Inc

LYEL

Lyell Immunopharma Inc

TRDA

Entrada Therapeutics Inc

Compare $LYEL vs $TRDA

Comparing Lyell Immunopharma Inc and Entrada Therapeutics Inc

LYELLyell Immunopharma Inc

TRDAEntrada Therapeutics Inc

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

TRDAEntrada Therapeutics Inc

Market cap

$220M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.15x

Rev growth (TTM)

-94.1%

YTD performance

-43.6%

52W performance

-8.0%

FCF yield

-61.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LYEL

TRDA

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

TRDA

Entrada Therapeutics Inc

Market Cap

LYEL$203M

TRDA$220M

Enterprise Value

LYEL$130M

TRDA$121M

Price

LYEL$8.71

TRDA$5.67

P/E Ratio

LYELN/A

TRDAN/A

P/S Ratio

LYEL7,526.09x

TRDA46.97x

EV/Sales

LYEL4,822.94x

TRDA25.79x

EV/EBITDA

LYEL0.00x

TRDA15.47x

P/B Ratio

LYEL0.97x

TRDA0.90x

P/FCF Ratio

LYELN/A

TRDAN/A

EV/FCF

LYEL-0.74x

TRDA-0.89x

PEG Ratio

LYELN/A

TRDAN/A

Forward P/E (NTM)

LYELN/A

TRDAN/A

Forward P/S (NTM)

LYEL16,911.71x

TRDA5.15x

Revenue (TTM)

LYEL$27K

TRDA$5M

Revenue Growth (YoY)

LYEL-55.0%

TRDA-94.1%

Forward Rev Growth

LYEL7184.7%

TRDA124.9%

Gross Margin (TTM)

LYEL0.0%

TRDA0.0%

Operating Margin (TTM)

LYEL0.0%

TRDA0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

TRDA-3686.8%

Net Margin (TTM)

LYEL-920285.2%

TRDA-3537.7%

FCF Margin (TTM)

LYEL-648763.0%

TRDA-2883.2%

Net Income (TTM)

LYEL$-248M

TRDA$-166M

FCF (TTM)

LYEL$-175M

TRDA$-135M

EPS (TTM)

LYEL-$10.64

TRDA-$3.93

ROE (TTM)

LYEL-9162.0%

TRDA-5761.0%

ROA (TTM)

LYEL-7050.0%

TRDA-4654.0%

ROIC (TTM)

LYEL-9162.0%

TRDA-5761.0%

Cash

LYEL$73M

TRDA$99M

Debt

LYEL$0

TRDA$0

Net Cash/Debt

LYEL$73M

TRDA$99M

Current Ratio (TTM)

LYEL5.36x

TRDA10.89x

Quick Ratio (TTM)

LYEL5.12x

TRDA10.47x

Debt/Equity (TTM)

LYEL0.00x

TRDA0.00x

Debt/Assets (TTM)

LYEL0.0%

TRDA0.0%

Interest Coverage (TTM)

LYELN/A

TRDAN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

TRDA0.00x

Beta

LYEL-0.04

TRDA-0.22

52W Performance

LYEL-52.3%

TRDA-8.0%

YTD Performance

LYEL-69.9%

TRDA-43.6%

% from 52W High

LYEL-80.6%

TRDA-65.5%

% from 52W Low

LYEL6.1%

TRDA10.1%

Asset Turnover (TTM)

LYEL0.00x

TRDA0.01x

FCF Yield (TTM)

LYEL-86.2%

TRDA-61.4%

Earnings Yield (TTM)

LYEL-122.3%

TRDA-75.3%

Dividend Yield (TTM)

LYELN/A

TRDAN/A

Rule of 40

LYEL-648,818.0

TRDA-2,977.3

EV/GP/RG

LYELN/A

TRDAN/A

Ticker research

View LYEL research View TRDA research

Metric	LYEL Lyell Immunopharma Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$203M	$220M
Enterprise Value	$130M	$121M
Price	$8.71	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	46.97x
EV/Sales	4,822.94x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	0.97x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	5.15x
Revenue & Growth
Revenue (TTM)	$27K	$5M
Revenue Growth (YoY)	-55.0%	-94.1%
Forward Rev Growth	7184.7%	124.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	-3686.8%
Net Margin (TTM)	-920285.2%	-3537.7%
FCF Margin (TTM)	-648763.0%	-2883.2%
Net Income (TTM)	$-248M	$-166M
FCF (TTM)	$-175M	$-135M
EPS (TTM)	-$10.64	-$3.93
ROE (TTM)	-9162.0%	-5761.0%
ROA (TTM)	-7050.0%	-4654.0%
ROIC (TTM)	-9162.0%	-5761.0%
Financial Health
Cash	$73M	$99M
Debt	$0	$0
Net Cash/Debt	$73M	$99M
Current Ratio (TTM)	5.36x	10.89x
Quick Ratio (TTM)	5.12x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	-0.22
52W Performance	-52.3%	-8.0%
YTD Performance	-69.9%	-43.6%
% from 52W High	-80.6%	-65.5%
% from 52W Low	6.1%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-86.2%	-61.4%
Earnings Yield (TTM)	-122.3%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View TRDA research

Valuation

P/S Ratio

TRDA

46.97x

LYEL

7,526.09x

EV/FCF

TRDA

-0.89x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

LYEL

-55.0%

TRDA

-94.1%

Forward Revenue Growth

LYEL

7184.7%

TRDA

124.9%

Profitability & performance

Gross Margin

LYEL

0.0%

TRDA

0.0%

ROE

TRDA

-5761.0%

LYEL

-9162.0%

FCF Yield %

TRDA

-61.4%

LYEL

-86.2%

52-Week Performance

TRDA

-8.0%

LYEL

-52.3%

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

TRDA

Entrada Therapeutics Inc

Market Cap

LYEL$203M

TRDA$220M

Enterprise Value

LYEL$130M

TRDA$121M

Price

LYEL$8.71

TRDA$5.67

P/E Ratio

LYELN/A

TRDAN/A

P/S Ratio

LYEL7,526.09x

TRDA46.97x

EV/Sales

LYEL4,822.94x

TRDA25.79x

EV/EBITDA

LYEL0.00x

TRDA15.47x

P/B Ratio

LYEL0.97x

TRDA0.90x

P/FCF Ratio

LYELN/A

TRDAN/A

EV/FCF

LYEL-0.74x

TRDA-0.89x

PEG Ratio

LYELN/A

TRDAN/A

Forward P/E (NTM)

LYELN/A

TRDAN/A

Forward P/S (NTM)

LYEL16,911.71x

TRDA5.15x

Revenue (TTM)

LYEL$27K

TRDA$5M

Revenue Growth (YoY)

LYEL-55.0%

TRDA-94.1%

Forward Rev Growth

LYEL7184.7%

TRDA124.9%

Gross Margin (TTM)

LYEL0.0%

TRDA0.0%

Operating Margin (TTM)

LYEL0.0%

TRDA0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

TRDA-3686.8%

Net Margin (TTM)

LYEL-920285.2%

TRDA-3537.7%

FCF Margin (TTM)

LYEL-648763.0%

TRDA-2883.2%

Net Income (TTM)

LYEL$-248M

TRDA$-166M

FCF (TTM)

LYEL$-175M

TRDA$-135M

EPS (TTM)

LYEL-$10.64

TRDA-$3.93

ROE (TTM)

LYEL-9162.0%

TRDA-5761.0%

ROA (TTM)

LYEL-7050.0%

TRDA-4654.0%

ROIC (TTM)

LYEL-9162.0%

TRDA-5761.0%

Cash

LYEL$73M

TRDA$99M

Debt

LYEL$0

TRDA$0

Net Cash/Debt

LYEL$73M

TRDA$99M

Current Ratio (TTM)

LYEL5.36x

TRDA10.89x

Quick Ratio (TTM)

LYEL5.12x

TRDA10.47x

Debt/Equity (TTM)

LYEL0.00x

TRDA0.00x

Debt/Assets (TTM)

LYEL0.0%

TRDA0.0%

Interest Coverage (TTM)

LYELN/A

TRDAN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

TRDA0.00x

Beta

LYEL-0.04

TRDA-0.22

52W Performance

LYEL-52.3%

TRDA-8.0%

YTD Performance

LYEL-69.9%

TRDA-43.6%

% from 52W High

LYEL-80.6%

TRDA-65.5%

% from 52W Low

LYEL6.1%

TRDA10.1%

Asset Turnover (TTM)

LYEL0.00x

TRDA0.01x

FCF Yield (TTM)

LYEL-86.2%

TRDA-61.4%

Earnings Yield (TTM)

LYEL-122.3%

TRDA-75.3%

Dividend Yield (TTM)

LYELN/A

TRDAN/A

Rule of 40

LYEL-648,818.0

TRDA-2,977.3

EV/GP/RG

LYELN/A

TRDAN/A

Ticker research

View LYEL research View TRDA research

Metric	LYEL Lyell Immunopharma Inc	TRDA Entrada Therapeutics Inc
Market & Valuation
Market Cap	$203M	$220M
Enterprise Value	$130M	$121M
Price	$8.71	$5.67
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	46.97x
EV/Sales	4,822.94x	25.79x
EV/EBITDA	0.00x	15.47x
P/B Ratio	0.97x	0.90x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	5.15x
Revenue & Growth
Revenue (TTM)	$27K	$5M
Revenue Growth (YoY)	-55.0%	-94.1%
Forward Rev Growth	7184.7%	124.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	-3686.8%
Net Margin (TTM)	-920285.2%	-3537.7%
FCF Margin (TTM)	-648763.0%	-2883.2%
Net Income (TTM)	$-248M	$-166M
FCF (TTM)	$-175M	$-135M
EPS (TTM)	-$10.64	-$3.93
ROE (TTM)	-9162.0%	-5761.0%
ROA (TTM)	-7050.0%	-4654.0%
ROIC (TTM)	-9162.0%	-5761.0%
Financial Health
Cash	$73M	$99M
Debt	$0	$0
Net Cash/Debt	$73M	$99M
Current Ratio (TTM)	5.36x	10.89x
Quick Ratio (TTM)	5.12x	10.47x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	-0.22
52W Performance	-52.3%	-8.0%
YTD Performance	-69.9%	-43.6%
% from 52W High	-80.6%	-65.5%
% from 52W Low	6.1%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-86.2%	-61.4%
Earnings Yield (TTM)	-122.3%	-75.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-2,977.3
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View TRDA research